Make Informed Investment Decisions with Affordable Access to Experts
A Second Expert Opinion on Radius' (RDUS) Market Potential for Recently Approved Osteoporosis Drug TYMLOS (abaloparatide)Ticker(s): RDUS, AMGN, LLY
Name: Dr Theresa Guise - MD
Institution: Indiana University
- Professor of Medicine and Jerry W. and Peg S. Throgmartin Professor of Oncology in the Department of Medicine, Division of Endocrinology at Indiana University.
- Directs a metabolic bone disease clinic at IU where all of the patients have bone disease and a majority are postmenopausal women. Treats ~10-12 patients/week with injectable osteoporosis drugs (anti-resorptives denosumab and reclast or anabolics forteo or abaloparatide).
- Clinical interests include diseases of calcium and bone metabolism, and has been the recipient of numerous grants for research on the skeletal health in cancer patients. Dr. Guise is a frequent lecturer and has been published in over 100 peer reviewed journals.
What is your medical background? How many patients do you treat with osteoporosis?Added By: kcmckee
What are your thoughts on current osteoporosis treatments? What is your typical approach to tackling the various types of osteoporosis patients you see?Added By: kcmckee
What are your thoughts on teriparatide vs abaloparatide? What benefits and concerns do you see for each?Added By: kcmckee
Do you think the osteosarcomas present in rats during testing of abaloparatide warrants serious concern? Do you prescribe abaloparatide? If not, what would it take for you to prescribe abaloparatide?Added By: kcmckee
What percentage of your osteoporosis patients would you consider eligible for abaloparatide? What is your ideal candidate for this drug?Added By: kcmckee
Do you think RDUS’ transdermal patch for abaloparatide will be approved? Do you envision a transdermal delivery method impacting efficacy?Added By: kcmckee
What are your thoughts on the recent rejection of AMGN’s osteoporosis drug? Could you see this receiving approval further down the road?Added By: kcmckee
What percent of the market do you see abaloparatide inhabiting relative to teriparatide? Do you think abaloparatide has the potential to expand into other markets (like men with osteoporosis)?Added By: kcmckee
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.